United Kingdom

People: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

4:43pm BST
Change (% chg)

$-0.43 (-1.17%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Newton, Roger 

Dr. Roger S. Newton, Ph.D., FAHA, FACN is a Director of the Company. and is a fellow of the American Heart Association and the American College of Nutrition. Dr. Newton was previously our Executive Chairman and Chief Scientific Officer from 2012 to December 2016 and President and Chief Executive Officer from our founding in 2008 to December 2012. Prior to joining our company, he was Senior Vice President, Pfizer Global R&D from 2004 to 2008. He was a Co-founder, President & CEO of the original Esperion from July 1998 until its acquisition by Pfizer in 2004. Prior to founding the original Esperion, Dr. Newton was Chairman of the Atherosclerosis Drug Discovery Team at Warner Lambert from 1981 to 1998. Dr. Newton is a director of a number of companies including Celsee Diagnostics (previously DeNovo Biosciences, Inc.) and Juventas Therapeutics, Inc. He is also a member of the Technology Advisory Boards of Arboretum Ventures and FirstSense Medical, LLC. Dr. Newton has a Ph.D. in nutrition from the University of California, Davis, a Master of Science degree in nutritional biochemistry from the University of Connecticut, and a Bachelor of Science degree in biology from Lafayette College.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 343,846
Long-Term Incentive Plans, USD --
All Other, USD 120,000
Fiscal Year Total, USD 463,846

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --